Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences

被引:9
作者
Singh, Awadhesh Kumar [1 ]
Singh, Ritu [1 ]
机构
[1] GD Hosp & Diabet Inst, Kolkata, India
关键词
insulin; genito-urinary infection; hypoglycemia; Sodium glucose co-transporter-2 inhibitors; type; 2; diabetes; TYPE-2; DIABETES-MELLITUS; GLP-1 RECEPTOR AGONIST; BASAL INSULIN; GLYCEMIC CONTROL; COTRANSPORTER; DOUBLE-BLIND; WEIGHT-GAIN; DAPAGLIFLOZIN; EFFICACY; SAFETY;
D O I
10.1586/17512433.2016.1131121
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Sodium-glucose co-transporter-2 inhibitors (SGLT-2I) are recently approved class of anti-hyperglycaemic agents for the treatment of type 2 diabetes mellitus (T2DM). SGLT-2I inhibits renal glucose reabsorption, thereby ensuing urinary glucose excretion in a dose-dependent manner. This caloric loss and osmotic diuresis, secondary to increased urinary glucose excretion, has a unique potential to counter insulin induced weight gain and fluid retention, with little potential of hypoglycemic exacerbation. Also, as these agents act independently of insulin secretion or action, they are effective even in long-standing diabetes with depleted beta-cell reserve. Improvement in insulin sensitivity, as observed with SGLT-2I can also facilitate insulin action. Furthermore, significant reduction in total daily insulin dosage and reduction of body weight as observed during combination therapy renders SGLT-2I, a near-ideal partner to insulin. This review aims to evaluate the safety and efficacy of currently used SGLT-2I as an add-on to insulin therapy in the treatment of T2DM.
引用
收藏
页码:409 / 418
页数:10
相关论文
共 40 条
  • [1] [Anonymous], CAN J DIABETES
  • [2] [Anonymous], AM J MED S6A
  • [3] Saxagliptin Add-on Therapy to Insulin With or Without Metformin for Type 2 Diabetes Mellitus: 52-Week Safety and Efficacy
    Barnett, Anthony H.
    Charbonnel, Bernard
    Li, Jia
    Donovan, Mark
    Fleming, Douglas
    Iqbal, Nayyar
    [J]. CLINICAL DRUG INVESTIGATION, 2013, 33 (10) : 707 - 717
  • [4] Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin
    Barnett, Anthony H.
    Charbonnel, Bernard
    Donovan, Mark
    Fleming, Douglas
    Chen, Roland
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (04) : 513 - 523
  • [5] Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes A Randomized, Controlled Trial
    Buse, John B.
    Bergenstal, Richard M.
    Glass, Leonard C.
    Heilmann, Cory R.
    Lewis, Michelle S.
    Kwan, Anita Y. M.
    Hoogwerf, Byron J.
    Rosenstock, Julio
    [J]. ANNALS OF INTERNAL MEDICINE, 2011, 154 (02) : 103 - +
  • [6] Insulin treatment and the problem of weight gain in type 2 diabetes
    Carver, Catherine
    [J]. DIABETES EDUCATOR, 2006, 32 (06) : 910 - 917
  • [7] From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
    DeFronzo, Ralph A.
    [J]. DIABETES, 2009, 58 (04) : 773 - 795
  • [8] Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin
    Devineni, D.
    Morrow, L.
    Hompesch, M.
    Skee, D.
    Vandebosch, A.
    Murphy, J.
    Ways, K.
    Schwartz, S.
    [J]. DIABETES OBESITY & METABOLISM, 2012, 14 (06) : 539 - 545
  • [9] Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
    Ferrannini, Ele
    Muscelli, Elza
    Frascerra, Silvia
    Baldi, Simona
    Mari, Andrea
    Heise, Tim
    Broedl, Uli C.
    Woerle, Hans-Juergen
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (02) : 499 - 508
  • [10] Is glycemic control improving in US adults?
    Hoerger, Thomas J.
    Gregg, Edward W.
    Segel, Joel E.
    Saaddine, Jinan B.
    [J]. DIABETES CARE, 2008, 31 (01) : 81 - 86